ASAleksander G. Sofronov

Aleksander G. Sofronov

*This is an algorithmically generated author record based on publicly available information.

Aleksander G. Sofronov has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Anhedonia Phenomenon in the Mirror of Clinical Experience: Results of a Survey of 1,021 Psychiatrists in Russia

    by E. D. Kasyanov, Yu. B. Barylnik, E. O. Boyko, I. V. Bukina, L. K. Galiullina, D. M. Ivashinenko, I. B. Karpukhin, E. G. Kornetova, D. A. Koryagina, G. P. Kostyuk, et al.

    Objective. To comprehensively assess practicing psychiatrists’ clinical views, diagnostic practices, and therapeutic approaches to anhedonia in the Russian Federation. Materials and methods. A crosssectional survey was conducted from March to September 2025. A purpose-designed 27-item questionnaire covered detection and clinical significance of anhedonia, its impact on prognosis, and pharmacological and psychotherapeutic strategies. Eligible participants were physicians actively practicing psychiatry in the Russian Federation. The sample was recruited via targeted mailings to institutional clusters with subsequent link forwarding (i.e., elements of snowball sampling); the final cohort represents a purposive sample. Statistical analyses were performed in R 4.2.1 using base R and the psych package. Results . A total of 1,021 physicians were included (mean age 40.8 years [SD 11.3]; years in practice 14.5 [SD 10.9]). Nearly all respondents explicitly assess anhedonia in depression (96.5%). In clinicians’ subjective estimates, anhedonia occurs in 40–80% of patients and is most pronounced in melancholic depression (55.6%). The transdiagnostic nature of anhedonia is acknowledged by most respondents (77.1%), most often in the context of schizophrenia/schizoaffective disorder and bipolar disorder. Anhedonia is viewed as a marker of unfavorable prognosis: impaired functioning (62.2%), slower improvement (59.5%), and increased suicide risk (51.8%). Consensus regarding psychotherapy was high (81.1%; cognitive behavioral therapy most frequently cited). Opinions on pharmacotherapy were divided: 52.0% considered some antidepressants more effective in pronounced anhedonia; the need for antipsychotics was more often not supported (56.9%). No substantial geographic differences between metropolitan areas and other regions were identified. Male physicians were somewhat less likely to endorse the necessity of psychotherapy for anhedonia. About half of the respondents noted that under antidepressant treatment, worsening or persistence of anhedonia was often accompanied by “emotional blunting” (feelings of flattened emotions, apathy) in patients. Conclusions . Russian psychiatrists regard anhedonia as a central and transdiagnostic symptom that affects prognosis and warrants proactive assessment. These findings support domain-oriented approaches to anhedonia and personalized algorithms for managing patients with depression.

  • Open Access

    Applicability of regression models for the analysis of ordinal PANSS data in schizophrenia: a cohort study

    by Anton N. Gvozdetskii, Galina A. Prokopovich, Alla E. Dobrovolskaya, Ivan S. Kushnerev, Aleksander G. Sofronov

    BACKGROUND: There is ongoing debate about the appropriate measurement level for symptom severity scores derived from clinical rating scales. The use of statistically inappropriate analytical methods for such data may distort results and lead to misinterpretations. AIM: To study the applicability of linear, beta, beta-binomial, and ordinal regression models for assessing changes in schizophrenia symptoms over time using the PANSS. METHODS: The study cohort comprised patients diagnosed with schizophrenia and schizoaffective disorder. Symptom severity was quantified using the Positive and Negative Syndrome Scale (PANSS). Observation period, sex, brexpiprazole prescription upon admission, brexpiprazole monotherapy, and dropout from the study prior to completion of follow-up were used as covariates. Bayesian mixed-effects regression models were fitted to the obtained dataset: Model 1 (normal distribution), Model 2 (ordered beta distribution), Model 3 (beta-binomial distribution), and Model 4 (ordinal regression). The applicability of the models was assessed using the fit index γ, the proportion of predicted values that corresponded with any possible schizophrenia symptom score on the PANSS. A model was considered consistent at a γ=1. Additionally, the 95% Highest Density Interval (HDI) was calculated for γ. RESULTS: The study enrolled 24 patients with schizophrenia (75% of whom were men) aged 20 to 45 years. The fit index γ was 0.00 (95% HDI 0.00–0.00) for Model 1; 0.17 (95% HDI 0.14–0.21) for Model 2; 1.00 (95% HDI 1.00–1.00) for Model 3; and 1.00 (95% HDI 1.00–1.00) for Model 4. Model 1 allows results that fall outside the range of the PANSS. Models 1 and 2 can produce fractional values. CONCLUSION: Statistical models designed to analyze continuous variables (linear and beta regression) are inapplicable for ordinal variables and, in particular, changes in schizophrenia symptoms over time on the PANSS. Beta-binomial and ordinal regression models are recommended for rating scores.


  • Open Access

    Predicting the Risk of Rehospitalization in Patients with Paranoid Schizophrenia Considering Disease Duration and Maintenance Antipsychotic Therapy

    by I. S. Kushnerev, A. N. Gvozdetckii, A. E. Dobrovolskaya, A. G. Sofronov

    Background: the search for predictors of readmission applicable in real clinical practice is still of interest to schizophrenia researchers. The prognostic value of antipsychotic therapy after discharge from the hospital and its relationship to the duration of the disease remain poorly understood. The aim was to identify risk factors for repeated hospitalization in patients with paranoid schizophrenia, taking into account the duration of the disease and the underlying antipsychotic therapy prescribed at the time of discharge from a psychiatric hospital. Patients and Methods: the study included 163 patients with paranoid schizophrenia (unselected sampling; women — 42.3% (n = 69), average age — 30.26 ± 7.05 years), discharged after inpatient treatment. Antipsychotic therapy was taken into account when the patient was discharged from the hospital, according to medical records for the period from 2018 to 2024. Antipsychotic drugs were divided into the first and second generations (respectively, FGA and SGA). Patients taking clozapine were excluded from the study. The method of taking the medicine (oral or injectable in the form of a depot) was taken into account. All doses of the drugs have been converted to standard daily doses (the equivalent of 5 mg of risperidone according to the WHO Defined daily dose method). The prognostic significance of the duration of the disease was also studied. The risk of re-hospitalization was assessed using the Cox regression method with mixed effects. Results: mean duration of follow-up was 3.87 [2.87; 4.08] years. The average dosage of the antipsychotic was 1.20 [0.99; 1.67] daily doses. Secondgeneration antipsychotics accounted for 76.2% in total structure of drug prescriptions. The share of extended forms of both generations accounted for 18.1% of appointments. With one SGA hospitalization, the risk of repeated hospitalization decreases with an increase in the standard dose (aHR = 0.24 (0.07; 0.83), p = 0.005). In the first episode, the overall risk of rehospitalization was lower relative to that of chronic patients (aHR = 0.49 (0.29, 0.82), p < 0.001). For the remaining combinations of factors “drug dose — antipsychotic generation — number of hospitalizations”, the trends are not unambiguous. Conclusions: the risk of rehospitalization at the first psychotic episode was reduced by 2.04 (1.22; 3.40) times regardless of the therapy received. When patients are prescribed SGA drugs (except clozapine) in a dose exceeding the standard daily dose, the risk of rehospitalization decreases by 4.17 (1.20; 14.29) times regardless of the duration of the disease.

  • Open Access

    The Relationship of the Structure of Antipsychotic Prescriptions with Socio-Demographic and Clinical-Dynamic Indicators in Patients with Paranoid Schizophrenia

    by I. S. Kushnerev, A. N. Gvozdetckii, A. E. Dobrovolskaya, A. G. Sofronov

    Background: it is well known that improving clinical guidelines should take into account the results of studies conducted in real-world clinical practice. Data of the prescription patterns and dosages of antipsychotic medications in patients with schizophrenia of varying disease duration are in the area of special interest. The aim was to study the relationship between the prescription patterns of antipsychotics and the socio-demographic, clinical and dynamic characteristics, quality of life indicators, and social functioning of patients with paranoid schizophrenia. Patients and Methods: the study included 208 inpatients with paranoid schizophrenia (total sample; mean age — 30.21 ± 6.84 years, males — 58.65% ( n = 122)). The structure of antipsychotic prescriptions was analyzed based on medical records from 2018 to 2024. For all medications, the standard daily dose was determined using the Defined Daily Dose (WHO) methodology. Socio-demographic, clinical and dynamic characteristics were assessed, along with PANSS, BACS, PSP, and WHOQOL-BREF scale scores. Results: a total of 16 antipsychotic drugs were identified in the prescription structure. Two patient groups were identified in the principal component space. Group 1 included patients with a significant (> 60%) predominance of risperidone and olanzapine prescriptions ( n = 136). Group 2 made up patients with a comparable predominance of haloperidol and clozapine prescriptions ( n = 72). Group 1 included 94 (69.1%) patients experiencing their first psychotic episode, whereas Group 2 included 50 (69.4%) chronic patients. Group 1 had significantly lower disease duration, number of hospitalizations ( p < 0.001), number of disabilities ( p = 0.003); significantly higher mean duration of outpatient treatment ( p < 0.001), higher scores on the BACS subtests “verbal learning” ( p = 0.009) and “working memory” ( p = 0.049). Conclusion: risperidone, olanzapine, and other second-generation antipsychotics are significantly more frequently prescribed in real-world clinical practice to patients with shorter disease duration and relatively preserved cognitive functions. In contrast, haloperidol and clozapine predominate in the prescriptions of chronic patients.

  • Open Access

    Antipsychotic Prescribing Practices for In-patients with Schizophrenia

    by A. G. Sofronov, A. E. Dobrovolskaya, A. N. Gvozdetckii, I. S. Kushnerev

    Results: consumption of antipsychotics in hospital for the period 2015–2022 characterized by a decrease in the proportion of typical antipsychotics (TA) to 12.8% due to an increase in the proportion of atypical antipsychotics (AA) to 61.0% and long-acting antipsychotics (LA) to 26.2%. The administration of antipsychotics by hospital treatment units was relatively uniform. Clozapine (26.9%), zuclopenthixol (20.0%), haloperidol (10.3%), olanzapine (10.3%), risperidone (9.3%), quetiapine (8.2%), paliperidone (4.1%) accounted for 89.1% of all antipsychotics consumed. The total proportion of cariprazine, pericyazine, aripiprazole, ziprasidone, levomepromazine, chlorprothixene, chlorpromazine, tiapride and trifluoperazine, sertindole, lurasidone, sulpiride, flupenthixol and brexpiprazole was 10.9%. Among the medications prescribed to patients with schizophrenia, the leading ones were risperidone (36.2%), haloperidol (17.1%), olanzapine (15.6%), and clozapine (10.8%). The frequency of prescription of other drugs was less than 10.0%. The share of TA was 26.3%, AA — 73.7%. In the vast majority of cases (98.1%), patients received monotherapy. Conclusion: the data obtained on the structure of antipsychotic prescriptions indicate that our approaches correspond to the global trend of the predominant use of second-generation antipsychotics in the in-patient treatment of schizophrenia.


  • Open Access

    Efficacy and Safety Profiles of Antipsychotic Drugs as Viewed by Psychiatrists: A Comparative Analysis of Cariprazine and Risperidone

    by Anton N. Gvozdeckii, Alla E. Dobrovolskaya, Galina A. Prokopovich, Aleksandr H. Sofronov

    BACKGROUND: Physicians hold the belief that the treatment outcomes and the treatment strategy they eventually adopt is largely determined by the differences in medications. Despite numerous studies focusing on the decision-making processes of psychiatrists, including the choice of antipsychotics when prescribing pharmacotherapy, the impact of therapeutic drug profiling on physicians’ decision-making remains poorly comprehended. AIM: The aim of this study is to assess the quantitative differences in perceptions of antipsychotics by psychiatrists using cariprazine and risperidone as examples. METHODS: A total of 79 psychiatrists were interviewed anonymously in St. Petersburg, Russia. The physicians documented the clinical advantages they perceived drugs to possess relative to one another, following a predetermined principle: A B, A=B, A B (2-AC protocol). The comparison is based on eleven parameters that assess the effectiveness and safety of cariprazine or risperidone. It has been hypothesized that the pattern of responses (qualitative difference) and the degree of preference for each drug (quantitative difference) may not align with the data in the original meta-analyses. RESULTS: The perception parameter exhibited a greater difference than anticipated (δ — 0.889), while the threshold for differentiating between the drugs was lower (τ — 1.001). The response pattern only aligned with theory by 44.37%. The dispersion of responses was associated with the length of work experience. CONCLUSION: The perceived difference between the drugs significantly deviates from the theoretical data, both in terms of strength of perception and pattern (quantitative and qualitative differences).

  • Open Access

    Suicidological analysis of Moscow and Saint Petersburg in the context of the pandemic

    by Vsevolod Anatolievitch Rozanov Rozanov, Natalia V. Semenova, Alexandr Ja. Vuks, Victoria V. Freize, Larisa V. Malyshko, Georgy P. Kostyuk, Vladimir D. Isakov, Orazmurad D. Yagmurov, Alexandr G. Sofronov, Nikolay G. Neznanov, et al.

    BACKGROUND: Suicide mortality in Moscow and St. Petersburg the two most populated federal cities of Russia is not characterized enough. However, these cities have been mostly affected by the pandemic. AIM: To analyze the latest trends in suicidal behavior in the historic capitals of Russia in an observational study, taking into account pandemic waves. METHODS: The monthly numbers of suicides (date of death, sex, age, and method), and number of cases in Moscow (n=1558) and St. Petersburg (n=2077) from January 01, 2016, to September 30, 2021, were used to calculate frequencies per 100,000 and to analyze tendencies across sex and age groups. Statistics were based on Z-criterion, and confidence intervals were calculated as per Wilson. RESULTS: Moscow and St. Petersburg belong to regions with suicide rates lower than the world average rates. Suicide mortality in both capitals was declining, but was more pronounced in Moscow. In St. Petersburg, the average rate was 3.28 higher, with 3.53 times in men and 2.84 times higher in women. The male-to-female ratio in St. Petersburg was also higher than that in Moscow (3.39:1 versus 2.87:1). In both cities, the highest rates were found among citizens aged 80 years, and the rates in young and adults (aged 2049 years) are also high. Those aged 6069 years have comparatively low rates. After a brief decline in the suicide rates during the first quarantine period in 2021, the decline in Moscow stopped, whereas in St. Petersburg, a gradual increase began, reaching significant levels among men in September. The most traditional method of self-harm (hanging) decreased, whereas the proportion of falls from a height increased (38.8% growth), as well as self-poisoning and self-cutting. A more detailed analysis of the urban method of suicide such as falling from a height revealed that in 2021, in St. Petersburg, a category of persons emerged among whom this method has grown dramatically (five times) in men aged 60 years. CONCLUSIONS: Suicides among the urbanized population of the largest metropolitan areas in Russia during the pandemic demonstrate trends that raise concerns, and the structure of mortality and methods of self-harm are changing. Further monitoring and intensification of preventive measures are needed, especially in St. Petersburg.


  • Association of gene polymorphisms DRD3 rs6280, COMT rs4680 and HTR2A rs7322347 with schizophrenia

    by A.G. Sofronov, A.E. Dobrovolskaya, A.YU. Morozova, E.A. Gorina, S.A. Kolchev, A.N. Gvozdetckii

    ЦЕЛЬ ИССЛЕДОВАНИЯ Поиск ассоциации генетических полиморфизмов rs6280 гена DRD3, rs4680 гена COMT, rs7322347 гена HTR2A с шизофренией. МАТЕРИАЛ И МЕТОДЫ В выборку вошли 300 стационарных больных параноидной шизофренией. Группа здорового контроля составила 290 испытуемых. Ассоциация между полиморфизмами и исследуемыми группами оценивалась логистической регрессией. РЕЗУЛЬТАТЫ Выраженность позитивной симптоматики по шкале PANSS в группе пациентов соответствовала 14,0 [11,0; 18,0] балла, негативной симптоматики — 21,0 [17,0; 27,0] балла, других симптомов — 33,0 [27,8; 38,0] балла. Выявлена межгрупповая разница (p=0,012) при сравнении генотипа по полиморфизму rs7322347 между группами. Генотип CC полиморфизма rs6280 ассоциирован с шизофренией (ОШ 3,37 (1,50; 8,03)). Генотип TT полиморфизма rs7322347 ассоциирован с контрольной группой (ОШ 1,83 (1,25; 2,68)). ЗАКЛЮЧЕНИЕ Данные проведенного анализа подтвердили гипотезу об ассоциации генетических полиморфизмов rs7322347 гена HTR2A (p=0,006) и rs6280 гена DRD3 (p=0,004) с заболеванием. Гипотезу о связи полиморфизма rs4680 гена COMT подтвердить не удалось.


  • Open Access

    A psychodiagnostic tool for the structural assessment of the social network in patients with schizophrenia: validity and psychometric properties

    by A. G. Sofronov, A. E. Dobrovolskaya, A. V. Trusova, I. A. Getmanenko, A. N. Gvozdetckii

    The aim of the study was to develop a new valid psychometric diagnostic tool for a multi-factor social network assessment of schizophrenic patients, called «The structural assessment of the social network of schizophrenic patients». The new development is based on the social network analysis model elaborated by S. L. Phillips (1981) and translated into Russian by Gurovich I. Ya. et al. (2007). The authors of this article additionally developed an algorithm for assessing the activity of patients on social networks of the Internet. Reducing non-informative variables and conducting a confirmatory factor analysis in a sample of 265 observations of schizophrenic patients (F20.0) aged from 18 to 55, recruited in four medical organizations (145 patients admitted to the hospital and 55 outpatients), resulted in determining a four-factor structure of the patients’ social network: «Objective parameters», «Internet activity», «Emotional aspect of social support» and«Reciprocal support». The method has demonstrated high internal and external validity, as well as applicability in the clinical practice in schizophrenia due to the low resource consumption and compact applicability. Measurable factor indicators of the patients’ social networks obtained by using the structural assessment of the social network of schizophrenic patients allow to determine the targets for psychocorrectional interventions and to increase the effectiveness of psychosocial rehabilitation. In addition an automated method for calculating final indicators has been developed, as well as manual, practical recommendations and corresponding printed forms.